Nisa Investment Advisors’s Sana Biotechnology SANA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$29.1K Hold
10,101
﹤0.01% 1882
2025
Q4
$41.1K Sell
10,101
-810
-7% -$3.63K ﹤0.01% 1681
2025
Q3
$38.7K Hold
10,911
﹤0.01% 1707
2025
Q2
$29.8K Buy
10,911
+9,501
+674% +$19.6K ﹤0.01% 1756
2025
Q1
$2.37K Buy
1,410
+400
+40% +$1.12K ﹤0.01% 2425
2024
Q4
$1.65K Sell
1,010
-148
-13% -$441 ﹤0.01% 2553
2024
Q3
$4.82K Sell
1,158
-258
-18% -$1.35K ﹤0.01% 2232
2024
Q2
$7.73K Buy
1,416
+280
+25% +$2.23K ﹤0.01% 2209
2024
Q1
$11.4K Buy
1,136
+96
+9% +$719 ﹤0.01% 2015
2023
Q4
$4.24K Buy
1,040
+37
+4% +$136 ﹤0.01% 2133
2023
Q3
$3.88K Hold
1,003
﹤0.01% 2304
2023
Q2
$5.98K Hold
1,003
﹤0.01% 2312
2023
Q1
$3K Buy
1,003
+43
+4% +$172 ﹤0.01% 2294
2022
Q4
$4K Hold
960
﹤0.01% 2319
2022
Q3
$6K Hold
960
﹤0.01% 2270
2022
Q2
$6K Sell
960
-20
-2% -$127 ﹤0.01% 2260
2022
Q1
$8K Sell
980
-830
-46% -$6.71K ﹤0.01% 2247
2021
Q4
$16K Buy
+1,810
New +$34.9K ﹤0.01% 1960

Other funds holding SANA

Nisa Investment Advisors's SANA Position: Q1 2026 in Review

Nisa Investment Advisors held its Sana Biotechnology (SANA) position steady in Q1 2026 at 10,101 shares worth $29.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1882.

Nisa Investment Advisors first reported a position in SANA in Q4 2021 and has held it in 18 quarters since. The position peaked at $41.1K in Q4 2025. 202 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

  • Nisa Investment Advisors held 10,101 shares of Sana Biotechnology worth $29.1K as of Q1 2026.
  • Nisa Investment Advisors left its Sana Biotechnology share count unchanged in Q1 2026.
  • Sana Biotechnology made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #1882 holding.
  • Nisa Investment Advisors first reported a position in Sana Biotechnology in Q4 2021 and has held it in 18 quarters since.
  • Nisa Investment Advisors's Sana Biotechnology position peaked at $41.1K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.